%0 Journal Article
%T Resveratrol Promotes Foot Ulcer Size Reduction in Type 2 Diabetes Patients
%A Yuriy K. Bashmakov
%A Samir H. Assaad-Khalil
%A Myriam Abou Seif
%A Ruzan Udumyan
%A Magdy Megallaa
%A Kamel H. Rohoma
%A Mohamed Zeitoun
%A Ivan M. Petyaev
%J ISRN Endocrinology
%D 2014
%R 10.1155/2014/816307
%X Objective. The effect of a proprietary formulation of trans-resveratrol (t-RSV) on manifestations of diabetic foot syndrome (DFS) was studied in type 2 diabetic patients with newly diagnosed diabetic foot ulcers. Method. Placebo-controlled, examiner-blinded, parallel-group randomized controlled pilot clinical trial (ACTRN Clinical Trial Registry number 12610000629033) involving 24 patients with DFS (15 males and 9 females, average age of years) divided into the placebo and RSV-treatment groups was performed. 50£¿mg of t-RSV or placebo capsules was given to each patient twice a day over a 60-day time period. Results. Reduction in the parameters reflecting diabetic ulcer size was more profound in the RSV group as compared to placebo. RSV-treated patients also had a marginally improved performance in the foot pressure test. A statistically significant decline in the plasma fibrinogen level, but not CRP, was also found in the RSV-treated patients. Some improvement in the plasma lipid profile and fasting glucose levels were not related to RSV-treatment, since they have been seen on both the RSV and placebo groups, revealing the effectiveness of medical supervision and education in the newly diagnosed patients with DFS. Conclusion. t-RSV supplementation promotes reduction of the foot ulcer size and reduces plasma fibrinogen level in type 2 diabetic patients. 1. Introduction The International Diabetes Federation estimates that there are currently 285 million diabetic patients worldwide. This represents a twofold increase in the number of individuals affected by diabetes since 2000 [1]. A further increase in the number of diabetic patients of ~7 million per year is projected for the near future. Up to 25% of diabetics are likely to develop diabetic foot syndrome at some time during the course of their disease [2, 3]. In general terms, diabetic ulcers represent the most severe and persistent cause of chronic ulceration in the human body. Poorly managed diabetic foot syndrome eventually leads to lower limb amputation [4]. Overall life expectancy of patients with diabetic foot syndrome, even in industrialized countries, is reduced by at least 10 years [5]. Five-year mortality rates in newly diagnosed patients might reach 55% and rise to 74% after lower limb amputation [6, 7]. These remarkable values exceed known mortality rates for breast, colon, and prostate cancers [8]. There are significant deficiencies in the understanding of the pathophysiological mechanisms behind diabetic ulceration. It is generally believed that neuropathy, peripheral arterial disease, and
%U http://www.hindawi.com/journals/isrn.endocrinology/2014/816307/